WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100105
CAS#: 68630-75-1 (free base)
Description: Buserelin is a Gonadotropin-releasing hormone agonist (GnRH agonist). The drug's effects are dependent on the frequency and time course of administration. GnRH is released in a pulsatile fashion in the postpubertal adult. Initial interaction of any GnRH agonist, such as buserelin, with the GnRH receptor induces release of FSH and LH by gonadotrophes.
MedKoo Cat#: 100105
Name: Buserelin
CAS#: 68630-75-1 (free base)
Chemical Formula: C60H86N16O13
Exact Mass: 1238.65603
Molecular Weight: 1239.42
Elemental Analysis: C, 58.14; H, 6.99; N, 18.08; O, 16.78
Buserelin, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Related CAS #: 68630-75-1 (free base) 68630-75-1 (acetate)
Synonym: buserelin acetate; busereline; US brand name: Etilamide Foreign brand names: Bigonist; Profact; Profact Depot; Receptal; Suprecur; Suprefact; Suprefact Depot; Suprefact Flakon; Abbreviation: BSRL Code names: HOE 766; ICI 123215; S746766; Chemical structure names: ; 6O(11dimethylethyl)Dserine9(NethylLprolinamide)10deglycinamide luteinizing hormonereleasing factor (pig); Dser (bu(t))(6) pro(9) NEt LHRH Acetate.
IUPAC/Chemical Name: 1-(3-((1H-imidazol-4-yl)methyl)-6-((1H-indol-3-yl)methyl)-15-(tert-butoxymethyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-(5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-ethylpyrrolidine-2-carboxamide
InChi Key: CUWODFFVMXJOKD-UHFFFAOYSA-N
InChi Code: InChI=1S/C60H86N16O13/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65)
SMILES Code: O=C(C1N(C(C(CCCNC(N)=N)NC(C(CC(C)C)NC(C(COC(C)(C)C)NC(C(CC2=CC=C(O)C=C2)NC(C(CO)NC(C(CC3=CNC4=C3C=CC=C4)NC(C(CC5=CNC=N5)NC(C(CC6)NC6=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)NCC
The following data is based on the product molecular weight 1239.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health (Lond Engl). 2010 Jan;6(1):27-35. Review. PubMed PMID: 20001868.
2: Thitaram C, Pongsopawijit P, Chansitthiwet S, Brown JL, Nimtragul K, Boonprasert K, Homkong P, Mahasawangkul S, Rojanasthien S, Colenbrander B, van der Weijden GC, van Eerdenburg FJ. Induction of the ovulatory LH surge in Asian elephants (Elephas maximus): a novel aid in captive breeding management of an endangered species. Reprod Fertil Dev. 2009;21(5):672-8. PubMed PMID: 19486604.
3: Taguchi T, Noguchi S. [Clinical applications of GnRHa in breast cancer]. Nippon Rinsho. 2006 Apr;64 Suppl 4:85-9. Review. Japanese. PubMed PMID: 16689290.
4: Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grøndahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006 Aug;21(8):2126-30. Epub 2006 May 8. PubMed PMID: 16682403.
5: Proos LA, Lönnerholm T, Jonsson B, Tuvemo T. Can bone age determination provide criteria for growth hormone treatment in adopted girls with early puberty? Ups J Med Sci. 2006;111(1):117-29. PubMed PMID: 16553251.
6: Kanitz W, Schneider F, Hoppen HO, Unger C, Nürnberg G, Becker F. Pregnancy rates, LH and progesterone concentrations in mares treated with a GnRH agonist. Anim Reprod Sci. 2007 Jan;97(1-2):55-62. Epub 2006 Feb 20. PubMed PMID: 16488561.
7: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Dec;27(10):711-38. PubMed PMID: 16395422.
8: Choo R, Chander S, Danjoux C, Morton G, Pearce A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol. 2005 Feb;12(1):2547-52. PubMed PMID: 15777493.
9: Tenhagen BA, Surholt R, Wittke M, Vogel C, Drillich M, Heuwieser W. Use of Ovsynch in dairy herds--differences between primiparous and multiparous cows. Anim Reprod Sci. 2004 Mar;81(1-2):1-11. PubMed PMID: 14749044.
10: Out HJ, Mannaerts BM. The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data. Hum Fertil (Camb). 2002 Feb;5(1):G5-10; discussion G10-2, G41-8. Review. PubMed PMID: 11939160.
Buserelin is a synthetic analog of gonadotropin-releasing hormone (GnRH). Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)